<bill session="114" type="h" number="971" updated="2018-11-21T21:22:57Z">
  <state datetime="2015-02-13">REFERRED</state>
  <status>
    <introduced datetime="2015-02-13"/>
  </status>
  <introduced datetime="2015-02-13"/>
  <titles>
    <title type="short" as="introduced">Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to authorize a 6-month extension of certain exclusivity periods in the case of approved drugs that are subsequently approved for a new indication to prevent, diagnose, or treat a rare disease or condition, and for other purposes.</title>
    <title type="display">Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015</title>
  </titles>
  <sponsor bioguide_id="B001257"/>
  <cosponsors>
    <cosponsor bioguide_id="A000373" joined="2016-03-07"/>
    <cosponsor bioguide_id="B001251" joined="2015-02-13"/>
    <cosponsor bioguide_id="D000619" joined="2015-04-13"/>
    <cosponsor bioguide_id="F000451" joined="2016-09-07"/>
    <cosponsor bioguide_id="F000449" joined="2015-03-17"/>
    <cosponsor bioguide_id="F000372" joined="2016-03-17"/>
    <cosponsor bioguide_id="G000564" joined="2015-04-21"/>
    <cosponsor bioguide_id="G000546" joined="2015-03-03"/>
    <cosponsor bioguide_id="G000576" joined="2015-03-03"/>
    <cosponsor bioguide_id="H000324" joined="2015-04-13"/>
    <cosponsor bioguide_id="H001068" joined="2015-06-02"/>
    <cosponsor bioguide_id="L000567" joined="2016-09-08"/>
    <cosponsor bioguide_id="M001157" joined="2015-02-13"/>
    <cosponsor bioguide_id="M001159" joined="2015-03-17"/>
    <cosponsor bioguide_id="N000185" joined="2015-04-21"/>
    <cosponsor bioguide_id="P000594" joined="2015-04-28"/>
    <cosponsor bioguide_id="P000611" joined="2015-03-03"/>
    <cosponsor bioguide_id="Q000023" joined="2015-04-15"/>
    <cosponsor bioguide_id="R000409" joined="2016-03-07"/>
    <cosponsor bioguide_id="S001176" joined="2015-05-13"/>
    <cosponsor bioguide_id="S000522" joined="2016-05-13"/>
  </cosponsors>
  <actions>
    <action datetime="2015-02-13">
      <text>Introduced in House</text>
    </action>
    <action datetime="2015-02-13" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2015-02-20">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
    <committee subcommittee="Health" code="HSIF14" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="s" session="114" relation="unknown" number="1421"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Administrative remedies"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug therapy"/>
    <term name="Food and Drug Administration (FDA)"/>
    <term name="Government information and archives"/>
    <term name="Intellectual property"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2015-02-13T05:00:00Z" status="Introduced in House">Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015

Amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to extend by six months the exclusivity period for an approved drug or biological product when the product is additionally approved to prevent, diagnose, or treat a new indication that is a rare disease or condition (also known as an &#8220;orphan disease&#8221;).

Allows the FDA to revoke an extension if the application for the new indication contained an untrue material statement.

Requires the sponsor of a product receiving an extension to notify the FDA one year prior to discontinuing production for commercial reasons.

Requires the FDA to notify the public of products that receive this extension and patents related to those products.

Limits a product to one extension under this Act. Sets forth that extensions under this Act are in addition to other extensions.

Applies only to products approved after enactment of this Act for a new indication that is a rare disease or condition.</summary>
  <committee-reports/>
</bill>
